GlaxoSmithKline/Genmab's anti-CD20 monoclonal antibody Arzerra (ofatumumab) is reasonably likely to have a clinical benefit in heavily pretreated patients with chronic lymphocytic leukaemia (CLL), the US FDA's outside advisors say.
In a 10 to three vote, the oncologic drugs advisory committee (ODAC) said objective response rates in a single-arm trial...